High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma.
Adenocarcinoma
/ blood
Adult
Aged
Aged, 80 and over
Combined Modality Therapy
Erythrocyte Indices
Esophageal Neoplasms
/ blood
Esophagogastric Junction
/ pathology
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoadjuvant Therapy
/ mortality
Prognosis
Prospective Studies
Stomach Neoplasms
/ blood
Survival Rate
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
21
07
2018
pubmed:
2
2
2019
medline:
10
7
2019
entrez:
2
2
2019
Statut:
ppublish
Résumé
Elevated mean corpuscular volume (MCV) is associated with a diminished prognosis for various tumor entities. This study aimed to evaluate the association between preoperative serum MCV levels and both overall (OS) and disease-free survival (DFS) for patients with resectable adenocarcinomas of the esophagogastric junction (AEG). This study included consecutive patients undergoing surgical resection between 1992 and 2016. Measured preoperative MCV levels were stratified into quintiles and correlated with patients' survival and clinicopathologic characteristics. The study analyzed 314 patients with a median OS of 36.8 months and a median DFS of 20.6 months. The multivariate analysis showed that preoperatively elevated MCV is a significant prognostic factor for OS (hazard ratio [HR], 1.05; 95% confidence interval [CI], 1.03-1.08; P < 0.001) and DFS (HR, 1.05; 95% CI, 1.03-1.08; P < 0.001). In the subgroup analysis of neoadjuvantly treated and untreated patients, MCV remained an independent prognostic factor for OS (HR, 1.08; 95% CI, 1.04-1.12; P < 0.001) and DFS (HR, 1.07; 95% CI, 1.03-1.12; P < 0.001) in both groups. In the univariate analysis, tumor stage and differentiation, adjuvant chemotherapy, MCV, mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) were significantly correlated with diminished OS and DFS. Preoperatively elevated MCV is an independent prognostic factor for patients with adenocarcinomas of the esophagus and the gastroesophageal junction.
Sections du résumé
BACKGROUND
BACKGROUND
Elevated mean corpuscular volume (MCV) is associated with a diminished prognosis for various tumor entities. This study aimed to evaluate the association between preoperative serum MCV levels and both overall (OS) and disease-free survival (DFS) for patients with resectable adenocarcinomas of the esophagogastric junction (AEG).
METHODS
METHODS
This study included consecutive patients undergoing surgical resection between 1992 and 2016. Measured preoperative MCV levels were stratified into quintiles and correlated with patients' survival and clinicopathologic characteristics.
RESULTS
RESULTS
The study analyzed 314 patients with a median OS of 36.8 months and a median DFS of 20.6 months. The multivariate analysis showed that preoperatively elevated MCV is a significant prognostic factor for OS (hazard ratio [HR], 1.05; 95% confidence interval [CI], 1.03-1.08; P < 0.001) and DFS (HR, 1.05; 95% CI, 1.03-1.08; P < 0.001). In the subgroup analysis of neoadjuvantly treated and untreated patients, MCV remained an independent prognostic factor for OS (HR, 1.08; 95% CI, 1.04-1.12; P < 0.001) and DFS (HR, 1.07; 95% CI, 1.03-1.12; P < 0.001) in both groups. In the univariate analysis, tumor stage and differentiation, adjuvant chemotherapy, MCV, mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) were significantly correlated with diminished OS and DFS.
CONCLUSION
CONCLUSIONS
Preoperatively elevated MCV is an independent prognostic factor for patients with adenocarcinomas of the esophagus and the gastroesophageal junction.
Identifiants
pubmed: 30706229
doi: 10.1245/s10434-019-07186-1
pii: 10.1245/s10434-019-07186-1
pmc: PMC6399169
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
976-985Références
Arch Pathol Lab Med. 2001 Mar;125(3):391-6
pubmed: 11231489
Anticancer Drugs. 2003 Feb;14(2):119-23
pubmed: 12569298
World J Gastroenterol. 2004 Jun 1;10(11):1647-51
pubmed: 15162542
Am J Clin Oncol. 2004 Aug;27(4):364-8
pubmed: 15289729
Lancet Oncol. 2005 Sep;6(9):659-68
pubmed: 16129366
Alcohol Clin Exp Res. 2005 Oct;29(10):1877-83
pubmed: 16269918
Ann Surg Oncol. 2007 Feb;14(2):381-9
pubmed: 17160496
Am J Epidemiol. 2007 Jun 15;165(12):1424-33
pubmed: 17420181
Ann Surg. 2007 May;245(5):707-16
pubmed: 17457163
J Fam Pract. 2008 Aug;57(8):548-50
pubmed: 18687234
Am Fam Physician. 2009 Feb 1;79(3):203-8
pubmed: 19202968
Ann Surg Oncol. 2011 Oct;18(10):2757-63
pubmed: 21638093
Cancer Epidemiol. 2012 Jun;36(3):306-16
pubmed: 22504051
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
World J Gastroenterol. 2013 May 14;19(18):2811-7
pubmed: 23687419
Cancer Res Treat. 2015 Jan;47(1):72-7
pubmed: 25143051
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Gut. 2015 Mar;64(3):381-7
pubmed: 25320104
Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1012-23
pubmed: 25931440
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
Clin Chem Lab Med. 2016 Jul 1;54(7):1247-57
pubmed: 26630695
Curr Treat Options Oncol. 2016 May;17(5):21
pubmed: 27032643
Clin Chem Lab Med. 2017 Jun 27;55(7):974-983
pubmed: 27988499
Ann Surg Oncol. 2017 Aug;24(8):2282-2290
pubmed: 28424936
Nat Rev Dis Primers. 2017 Jul 27;3:17048
pubmed: 28748917
Surg Today. 2018 Feb;48(2):186-194
pubmed: 28795308
Am J Surg. 2018 Jul;216(1):124-130
pubmed: 28802729
Oncotarget. 2018 Jan 8;9(6):6968-6976
pubmed: 29467943
Cytometry. 1983 Nov;4(3):263-7
pubmed: 6661992
Lung Cancer. 1995 Mar;12(1-2):67-76
pubmed: 7600032
Ann Thorac Surg. 1994 Dec;58(6):1574-8; discussion 1578-9
pubmed: 7979718
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
Am J Clin Pathol. 1993 Dec;100(6):618-25
pubmed: 8249908
Gut. 1993 Jun;34(6):843-7
pubmed: 8314520
Br J Surg. 1998 Nov;85(11):1457-9
pubmed: 9823902